Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Daniel R Reed, Ramey Z Elsarrag, Amy L Morris & Michael K Keng. (2019) Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment. Cancer Management and Research 11, pages 8073-8080.
Read now
Read now
Articles from other publishers (11)
Yiming Cheng, Xiaomin Wang, Atalanta Ghosh, Jie Pu, Leonidas N Carayannopoulos & Yan Li. (2024) Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The Journal of Clinical Pharmacology.
Crossref
Crossref
Yiming Cheng, Shengnan Du, Hongxiang Hu, Xiaomin Wang, Leon Carayannopoulos & Yan Li. (2024) Integrating Full Bayesian Inference and Student's t‐Distribution Method for Enhanced Outlier Handling in Caffeine Population Pharmacokinetics: Assessing Drug–Drug Interactions with Enasidenib in Relapsed or Refractory AML and MDS Patients. The Journal of Clinical Pharmacology.
Crossref
Crossref
Xueke Shi, Jin Yang, Shuzhi Deng, Hongdan Xu, Deyang Wu, Qingxiang Zeng, Shimeng Wang, Tao Hu, Fanglong Wu & Hongmei Zhou. (2022) TGF-β signaling in the tumor metabolic microenvironment and targeted therapies. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Yiming Cheng, Xiaomin Wang, Zeen Tong, Josephine Reyes, Leon Carayannopoulos, Simon Zhou & Yan Li. (2021) Assessment of Transporter‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The Journal of Clinical Pharmacology 62:4, pages 494-504.
Crossref
Crossref
Bin Fan, Yue Chen, Feng Yin, Lei Hua, Caroline Almon, Salah Nabhan, Michael Cooper, Hua Yang & Mohammad Hossain. (2022)
Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed
IDH1/2
‐Mutant Acute Myeloid Leukemia
. Clinical Pharmacology in Drug Development 11:4, pages 429-441.
Crossref
Crossref
Lamia Madaci, Julien Colle, Geoffroy Venton, Laure Farnault, Béatrice Loriod & Régis Costello. (2021) The contribution of single-cell analysis of acute leukemia in the therapeutic strategy. Biomarker Research 9:1.
Crossref
Crossref
Zhiqiang Wang, Zhibo Zhang, Yong Li, Li Sun, Dezhen Peng, Danyu Du, Xian Zhang, Luwei Han, Liwen Zhao, Ligong Lu, Hongzhi Du, Shengtao Yuan & Meixiao Zhan. (2021) Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China. Acta Pharmaceutica Sinica B 11:6, pages 1526-1540.
Crossref
Crossref
Juan Eduardo Megías-Vericat, Antonio Solana-Altabella, Octavio Ballesta-López, David Martínez-Cuadrón & Pau Montesinos. (2020) Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Annals of Hematology 99:9, pages 1989-2007.
Crossref
Crossref
Xiaomin Wang, Jian Chen, Josephine Reyes, Simon Zhou, Maria Palmisano & Yan Li. (2019) A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach. Oncology and Therapy 8:1, pages 91-102.
Crossref
Crossref
Shuang-long Li, Yong-liang Zhu, Yi Zhang, Shu-han Liu, Xiang-die Wang & Xiang-jun Qiu. (2020) Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application. International Journal of Analytical Chemistry 2020, pages 1-7.
Crossref
Crossref
Yan Li, Liangang Liu, Diana Gomez, Jian Chen, Zeen Tong, Maria Palmisano & Simon Zhou. (2018) Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects. Pharmacology Research & Perspectives 6:6.
Crossref
Crossref